Summary by Moomoo AI
Arcutis Biotherapeutics, Inc., a Delaware corporation, has announced its Annual Meeting of Stockholders to be held virtually on June 14, 2024. The meeting will address the election of three Class I directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, the advisory approval of executive compensation, and other business as may arise. Stockholders as of April 22, 2024, are entitled to vote. The Board recommends voting for the proposed director nominees, the ratification of Ernst & Young LLP, and the approval of executive compensation. The company has also filed its definitive proxy statement with the SEC. Additionally, the company has provided a summary of the compensation of named executive officers and the opportunity for a non-binding advisory vote on executive compensation at the upcoming meeting.